

Non-Sterile Compounding

- For each standard,
- Mark "Yes" in the compliance box if your facility is 100% compliant with that standard.
- If facility never compounds under a specific requirement mark "NA" in the N/A box or NA by the section header.
- If you are compliant with an item, but not in the exact manner stated due to an exception described below, please note "Exception" in the compliant box.
- If non-compliant, provide an explanation and action plan for correction.
- If an exception, provide documentation of equivalence or superiority.
- Indicate your policy and procedures reference number in the yes/no boxes in the sterile compounding section of the form.
- Note: The included references to NAC are a guide. Additional regulations and/or statutes may apply. It is your responsibility to understand and comply with all administrative codes and statutes related to the compounding you intend to do.

Have all environmental, training, competencies, exceptions, action plans, and all other related documents available for review.

The inspection notice must be attached to your inspection form.

When filling out this form, circle yes for compliant and no for non-compliant. You may make comments as needed

| Standard Operating Procedures | | |
|-----------------------------------------------------------------------------------------------------------------------------|-----|----|
| The licensed pharmacy has a detailed written Standard Operating Procedures Manual (or Policy | | |
| and Procedure Manual) with detailed instructions that describe how, when (frequency), and by | | |
| whom all requirements in NAC 639.67015 and 639.67035 are to be met. | Yes | No |
| All compounded prescriptions are only prepared to fill: (a) a patient specific prescription, (b) a chart | | |
| order for immediate use by the patient, or (c) to prepare for the filling of future patient specific | | |
| prescriptions or chart orders based upon the previous use of the history of a practitioner and patient who | | |
| regularly uses the pharmacy. NAC 639.757 (list any exception that is allowed under the NAC that the pharmacy is utilizing) | Yes | No |
| | | |
| The patient is properly counseled about the compounded preparation at the time of | | |
| dispensing, If applicable. NAC 639.707 and 639.708 | Yes | No |
| Proper Use | Yes | No |
| Storage | Yes | No |
| Evidence of instability | Yes | No |
| NAC 639.707 Counseling requirements | Yes | No |
| NAC 639.708 Counseling records | | |
| Date of receipt of bulk product is noted on the container (USP 795) | Yes | No |
| Packages of ingredients that lack a supplier expiration date are assigned a conservative | | |
| expiration date not to exceed 3 years based on the nature of the component and its | | |
| degradation mechanism, the container in which it is packaged and the storage conditions. | | |
| Appropriate inspection and testing should be done to ensue the ingredient has retained purity | | |
| and quality. Have documentation available. (USP 795) | Yes | No |
| | | |



| If a product is transferred from the original manufacturer's conta | iner, the container is identified with the | | |
|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|----------------|-------------|
| component name, original supplier, lot or control number, transf | fer date, and expiration date and shall | | |
| provide integrity that is equivalent to or better than that of the o | riginal container | Yes | No |
| Compounded product's active ingredients must meet one of th | e following three standards: NAC 639.757 | USP 795 | |
| 1. Non-sterile ingredients, substances and excipients | s are official USP or NF grade (All | | |
| Certificates of Analysis (COA) are on file. | | Yes | No |
| 2. If non USP or NF food, cosmetics or other substan | ces are used, the active ingredients | | |
| are from an approved FDA manufacturer or distri | butor and are accompanied by a | | |
| Certificates of Analysis. All Certificates are on file. | | Yes | No |
| 3. If neither 1 nor 2 are met, the active ingredients h | • | | |
| compounding pharmacy through independent an | alysis by a laboratory to the | | |
| satisfaction of the Board. | | Yes | No |
| Circle sources of non USP or NF substances: | Other (list): | | |
| Analytical Reagent (ARA): | | | |
| Certified American Chemical Society (ACS): | | | |
| Food Chemicals Codex grade (FCC): | | | |
| Equipment NAC 63 | 9.6701 NAC 639.67033 | | |
| Records are available for review for all equipment used in | compounding. The records include, | | |
| but are not limited to, equipment setup, calibration, filter | | | |
| required and cleaning of the equipment. | | Yes | No |
| Cleaning/Calibration/Maintenance daily log | | Yes | No |
| Required certifications are on file for all equipment | nt that require certification (attach) | Yes | No |
| Check weight certification and recertification (aga | inst absolute standard testing | | |
| weight) | | | |
| (Dept of Agriculture Nevada does certification of weights 775-688-253 | | Yes | No |
| Balances/Scales (at least one of which must be sensitive to 1/2 grai apothecary and avoirdupois, from 1/2 grain to 4 ounces and from 0.02 | | Yes | No |
| Powder hoods, Laminar Flow or other Primary Engineerin | | Yes | No |
| Other (attach list) | | Yes | No |
| All training and environmental records must be readily av | ailable for review for the last 2 years | Yes | No |
| Records of all equipment calibrations, maintenance, testi | | Yes | No |
| | g and Documentation NAC 639.67013 | II | |
| Documentation is on file for EACH person who compounds | | uately skilled | d, |
| educated, instructed, and trained to correctly perform and | | - | |
| Provide a list certifying the personnel on the list are comp | etent and proficient to correctly perforn | n all the tas | ks related |
| to non-sterile compounding. The list must identify all com | petencies including didactic, observation | nal and mai | nipulative |
| training received. The list should include all elements listed | d under training for non-hazardous com | pounding fo | or the risk |
| level (identify the risk level) you are certifying the person t | o perform and a separate list for hazar | dous certific | ation (if |
| applicable). Please review the non-sterile compounding ac | - | - | |
| should be addressed at a minimum. Additional training sh | | | |
| personnel, documentation and training). Sign and date th | - | also certifie | s that all |
| documents related to this certification are on file and avai | lable for review. | · | |



| <i>Training</i> NAC 639.67013 NAC 639.67037 | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------|
| All pharmacists, pharmacist interns, technicians and technicians in training or any other person | | |
| who legally may compound dangerous drugs or hazardous drugs have been trained in: | Yes | No |
| Perform proper hand cleansing before and after compounding | Yes | No |
| Perform disinfection of compounding surfaces | Yes | No |
| Select and appropriately don protective garb | Yes | No |
| Identify, weigh and measure ingredients | Yes | No |
| Label and quality inspect non-sterile products | Yes | No |
| Treatment of employees of the pharmacy with regard to contact and inhalation | | |
| exposure. | Yes | No |
| Procedures for containment, cleaning and disposal with regard to breaks and spills | Yes | No |
| All pharmacists, pharmacist interns, technicians and technicians in training or any other person who | legally hand | lles or |
| dispense hazardous drugs additionally have been trained in: | | |
| The storage of hazardous drugs | Yes | No |
| The handling of hazardous drugs | Yes | No |
| The safety procedures of hazardous drugs | Yes | No |
| The disposal of hazardous drugs | Yes | No |
| • Safe manipulation practices that minimize exposure to the hazardous drug and | | |
| protects the employees from any overt exposure to the hazardous drug | Yes | No |
| Procedures for containment, cleaning and disposal with regard to breaks and spills | Yes | No |
| Treatment of employees with regard to exposure by contact and inhalation | Yes | No |
| Protection of personnel and compounding environment from contamination by | | |
| hazardous drugs | Yes | No |
| Any pharmacist, pharmacist intern, technician or technician in training that compounds a | | |
| hazardous drug that will be administered or dispensed to a patient has receive initial training | | |
| and | | |
| Is trained at least once a year: | Yes | No |
| The pharmacy shall make and keep a record of any training given related to dangerous drug or hazardous drug compounding. | Yes | No |
| | 163 | NO |
| Master Compounding (formulation) Record USP 795 | 1 | |
| Records are maintained for 2 years | Yes | No |
| A Master Formulation record is kept. The record is followed each time that each specific formulation | is compound | ded. The |
| record contains but is not limited to: | | |
| 1. Official or assigned name, strength, and dosage form of the preparation | Yes | No |
| 2. All necessary calculations including calculations needed to determine and verify quantities of | | |
| components and doses of active pharmaceutical ingredients. | Yes | No |
| Description of all ingredients and quantities Compatibility and stability information, including references (when available) | Yes | No |
| | Yes | No |



| | Yes | No |
|----------------------------------------------------------------------------------------------------------|---------------|-----|
| Order of mixing | Yes | No |
| Mixing temperatures or other environmental controls | Yes | No |
| Duration of mixing | Yes | No |
| Other factors pertinent to the replication of the preparation as compounded | Yes | No |
| 7. Container to use in dispensing and packaging requirements | Yes | No |
| 8. Labeling information including the name of and quantity or concentration of each ingredient | Yes | No |
| 9. Description of final preparation | Yes | No |
| 10. Storage requirements | Yes | No |
| 11. Quality control procedures and expected results | Yes | No |
| 12. A copy of all documentation validating any extended beyond use date is readily available for review | Yes | No |
| Compounding Record NAC 639.6701 NAC 639.6702 NAC 639.67019 | | |
| A detailed compounding record is maintained on the prescription or in the computer for each compounde | d preparation | |
| ncluding but not limited to: | apreparation | |
| 1. Official or assigned name, strength, and dosage of the preparation | Yes | No |
| Master Formulation record reference for the preparation | Yes | No |
| 3. Sources, lot numbers, and expiration dates of all components in the formulation | Yes | No |
| 4. Total quantity or number of doses units compounded | Yes | No |
| 5. The order of each step in the compounding of each non-sterile product, if applicable | Yes | No |
| 6. The name and initials of the person(s) who prepared the preparation | Yes | No |
| 7. The name of the person and initials who performed the quality control procedures | Yes | No |
| 8. The name and initials of the compounder who approved the preparation | 103 | 110 |
| 9. The date of the compounding | Yes | No |
| 10. The assigned internal identification (lot number) number or prescription number | Yes | No |
| 11. Description of the final preparation | Yes | No |
| 12. The assigned Beyond Use Date | Yes | No |
| 13. A duplicate label as described in the Master Formulation record (either a batch label | Tes | NU |
| or a prescriptive label) is attached | Yes | No |
| 14. Results of quality control procedures (e.g., weight range of the filled capsules, PH of | 163 | NO |
| aqueous liquids, etc.) | Yes | No |
| 15. Documentation of any quality control issues and any adverse reactions or preparation | 165 | NO |
| problems reported by the patient or caregiver. If applicable | Yes | No |
| 16. Any deviations from the master formulation record are documented | Yes | No |
| Documentation is available on site to support beyond use dates used on each product | Yes | No |
| Vaterial Safety Data Sheets (MSDSs) now called SDS sheets are available to compounding personnel for all | | NO |
| | | No |
| drugs and chemicals used in compounding | Yes | |



| Non-Sterile Compounding Categories USP 795 | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------|
| This facility compounds pharmaceuticals in the following compounding categories: | | |
| o Simple | Yes | No |
| Making a preparation that has a USP compounding monograph or that appears in a peer-reviewed journal article that contains specific quantities of all components, compounding procedure and equipment, and stability data for that formulation with appropriate BUDs: or reconstituting or manipulating commercial products that may require the addition of one or more ingredients as directed by the manufacturer. | | |
| ○ Moderate | Yes | No |
| Making a preparation that requires special calculations or procedures (such as calibration of dosage unit mold cavities) to determine quantities of components per preparation or per individualized dosage units; or making a preparation for which stability data for that specific formulation is not available. • Examples include diphenhydramine troches and mixing two or more manufactured cream products when the | | lata for |
| stability of the mixture is not known Complex | Yes | No |
| Making a preparation that requires special training, environment, facilities, equipment, and procedures to ensure appropriate therapeutic outcomes. Examples include transdermal dosage forms, modified-release preparations and some inserts and suppositories for systemic effects | Yes | No |
| Non-Sterile Compounded Drug Labeling NAC 639.6703 | | |
| Non-sterile compounded product labels include, without limitation any amount of non-sterile com product in excess of the amount required by the prescription or chart order and any non-sterile con is compounded in bulk. Each label contains at minimum the following: | • | - |
| The internal control number assigned to the compounded product | Yes | No |
| The beyond use date of the compounded product is calculated from the day of preparation of the non-sterile compound | Yes | No |
| As appropriate, the concentration of each active ingredient in the final compounded product | Yes | No |
| Common name of final product or the name of each active ingredient | Yes | No |
| Storage conditions | Yes | No |
| Beyond Use dating /labeling 639.6703 | | |
| A pharmacy may use a beyond use date later than the dates listed below if the pharmacy can prov testing or published data that the non-sterile compounded product is safe and effective using the e date. NAC 639.6703 sub 3 | | |
| If multiple strengths of a formula are compounded, documentation is available supporting extended use dating for each formula. | Yes | No |
| For non-aqueous liquids and solid dosage forms | | |
| Not later than the expiration date of the active ingredient with the earliest expiration date, or 6 months after the date the product was compounded, whichever is earlier | Yes | No |
| | | |
| | | |



| For compounds which contain non-sterile water | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------|
| Not later than 14 days after the date on which the non-sterile compounded | | |
| drug was compounded | Yes | No |
| For water containing topical/dermal and mucosal liquid and semisolid formulations | Yes | No |
| The beyond use date is not later than 30 days | Yes | No |
| 4. For compounds other than the above items 1 2, and 3, not later than the intended | | |
| duration of therapy or 30 days after the date the product was compounded, whichever | | |
| is earlier | Yes | No |
| Storage of Non-Sterile Compounded Products NAC 639.67015 NAC 639.6702 | | |
| Non-Sterile products, including, without limitation any non-sterile compounded product in exces | s of the am | ount |
| required by a prescription or chart order, and any compounded product made in bulk quantities | is stored to | ensure: |
| The efficacy of the product is maintained | Yes | No |
| The product remains free of contamination | Yes | No |
| Designated Area for Non-Sterile Compounding NAC 639.67033 | | |
| There is a designed area for compounding non-sterile products | Yes | No |
| Compounding areas are maintained in a clean and sanitary condition | Yes | No |
| All items of equipment inspected, maintained, cleaned and validated at appropriate intervals | Yes | No |
| Hot and cold potable water is available in the compounding area | Yes | No |
| Soap or detergent is available | Yes | No |
| Air driers or single-service towels are installed | Yes | No |
| Trash is disposed of in a safe, sanitary and timely manner | Yes | No |
| The designed area is cleaned using an antiseptic cleaning method before and after any | | |
| compounding occurs | Yes | No |
| Equipment used to compound non-sterile drug products is cleaned immediately after | | |
| compounding to prevent cross contamination | Yes | No |
| If the pharmacy compounds both sterile and non-sterile drug products, none of the equipment | | |
| used to compound non-sterile products is used to compound sterile products, unless the | | |
| equipment is cleaned and sanitized prior to using for sterile compounding | Yes | No |
| Each employee who compounds non-sterile products washes his/her hands with soap and | | |
| water or an antimicrobial agent before and after compounding the non-sterile product. | Yes | No |
| Policies and Procedures NAC 639.67015 NAC639.67035 21CFR 211.113(a) USP 795 | Yes | No |
| The pharmacy maintains written policies and procedures for compounding non-sterile | | |
| compounded products. | Yes | No |
| The policies and procedures include but are not limited to: | | |
| 1. Each final product has the identity, strength, quality and purity which the | | |
| compounded drug product is purported or represented to have. | Yes | No |
| 2. The components used to compound each non-sterile compounded drug | | |
| product are recorded on the prescription or in the computer record. | Yes | No |
| The amount of each component used to compound each non-sterile product. The order of each step in the process of compounding each non-sterile | Yes | No |
| The order of each step in the process of compounding each non-sterile product. | Yes | No |
| 5. Beyond Use Dating | Yes | No |
| | 103 | |

Non-Sterile Compounding NAC 639-66611-639.67079 Addendum 12/20/2017 Page 6 of 12



| C Chamical and shusical stability | No. | Nie |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------|
| 6. Chemical and physical stability | Yes | No |
| 7. Cleaning and disinfecting | Yes | No |
| 8. Component quality evaluation | Yes | No |
| 9. Compounding methods | Yes | No |
| 10. Dispensing | Yes | No |
| 11. Documentation | Yes | No |
| 12. Environmental quality and maintenance | Yes | No |
| 13. Equipment maintenance, calibration, and operation | Yes | No |
| 14. Formulation development | Yes | No |
| 15. Labeling | Yes | No |
| 16. Material and final compounded preparation handling and storage | Yes | No |
| 17. Measuring and weighing | Yes | No |
| 18. Packaging and repackaging | Yes | No |
| 19. Patient monitoring, complaints and adverse event reporting | Yes | No |
| 20. Patient or caregiver education and training | Yes | No |
| 21. Personnel cleanliness and garb | Yes | No |
| 22. Purchasing | Yes | No |
| 23. Quality Assurance and Continuous Quality Monitoring Safety | Yes | No |
| 24. Shipping | Yes | No |
| 25. Testing | Yes | No |
| 26. Training and retraining | Yes | No |
| • The information listed as items 1, 2, and 3 above is recorded on the hard copy of the | | |
| prescription maintained in the written records of the pharmacy or in the computer | | |
| system. Item 4 is in the record or references the Compounding record. | Yes | No |
| Control Procedures NAC 639.67035 USP795 | | |
| Control procedures for monitoring each final non-sterile product and for validating the compour | nding proces | s are in |
| place. The control procedures must include, without limitation: | | |
| Only one preparation is compounded at one time in a specific workspace | Yes | No |
| Only one preparation is compounded at one time in a specific workspace Any variation of more than plus or minus 10% in the weight of capsules, tablets | | |
| or any other solid form of a dosage unit | Yes | No |
| The adequacy of mixing to ensure uniformity and homogeneity of each | 105 | 110 |
| compounded product | Yes | No |
| If applicable, the clarity, completeness and pH of the compounded product | Yes | No |
| | Yes | No |
| | 163 | NO |
| Any variation of more than plus or minus 10% in the actual yield of a compounded product as compared to the theoretical yield of the compounded | | |
| product | Yes | No |
| | Tes | NU |
| Control procedures to ensure: If the final compounded product is a concula, that the concula is properly. | | |
| If the final compounded product is a capsule, that the capsule is properly locked | Voc | No |
| | Yes | No |
| If the final compounded product is a tablet or other solid form of dosage, the final compounded product is of a uniform size and is integet. | M | NI - |
| the final compounded product is of a uniform size and is intact | Yes | No |
| If the final compounded product is a suppository, the suppository is properly seeled | M | NI - |
| properly sealed | Yes 7 of 12 | No |

Non-Sterile Compounding NAC 639-66611-639.67079 Addendum 12/20/2017 Page 7 of 12



| . If the final compounded product is an oral liquid to the outent possible | | |
|------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----|
| If the final compounded product is an oral liquid, to the extent possible, the liquid is palatable to the patient | Voc | No |
| the liquid is palatable to the patient | Yes | No |
| If final compounded product is a suspension, the visible suspended | Vee | Na |
| particles are of uniform size and are readily dispersed upon shaking | Yes | No |
| If final compounded product is a topical compounded product, the | | |
| final product is smooth and not gritty and has a uniform viscosity | | |
| unless grittiness is required for a particular therapeutic purpose. | Yes | No |
| Non-Sterile Hazardous Drugs NAC 639.67037 | | |
| The components of hazardous drugs are stored separately from all the other inventory and in | | |
| such a manner and location to minimize the contamination of other drugs in and employees of | | |
| the pharmacy | Yes | No |
| Components are handled with caution by using appropriate gloves while distributing, receiving, | | |
| stocking, inventorying, and preparing for administrating and disposing of components of a | | |
| hazardous drug or final compounded product | Yes | No |
| Employees involved with compounding or otherwise handling hazardous drugs wear personal | | |
| protective equipment, including, without limitation, gowns, face masks, eye protection, double | | |
| gloves or chemotherapy gloves | | |
| | Yes | No |
| All hazardous waste is disposed of in a manner that complies with any applicable state, federal | | |
| or local law or regulation | Yes | No |
| All employees who are known to be a special risk with regard to the properties of hazardous | | |
| drugs are limited from exposure to those drugs | Yes | No |
| Does the pharmacy perform hazardous non-sterile compounding in a ventilated cabinet such as | | |
| a BSC, CAI (non-volatile APIs) or CACI? Note: this is a NIOSH requirement that is referenced in | | |
| USP 795. | Yes | No |
| Is testing of the BSC, CAI or CACI certified or tested periodically? | Yes | No |
| Single Dose and Multiple Dose Containers NAC 639.67057 | | |
| When a drug product in a single-dose container, including, without limitation, a bag, bottle, | | |
| syringe or vial of a sterile drug product seal is breached, the time and date of the breach is | | |
| marked on the container | Yes | No |
| • Single-dose sterile containers entered in worse than ISO Class 5 air quality and | | |
| stored in worse than ISO 7 are used within 1 hour of entry | Yes | No |
| Opened single-dose ampoules are not stored. If the entire seal has been removed for a multi-use | | |
| vial the contents are not stored | Yes | No |
| Closure sealed multiple-dose containers are used within 28 days after initial opening or | | |
| entry. | Yes | No |
| Records including, but not limited to: logs/SOPs, relevant documents related to your | Readil | |
| facility | y Aveile | |
| | Availa ble | No |
| Please ensure that all records/logs/SOPs (if relevant to your practice) are organized, | | |
| complete and readily available for review. This includes but is not limited to: | Yes | No |
| SOPs relevant to your practice and processes | Yes | No |
| | 162 | NU |
| Recommended: Humidity (35-60% range) and room temperature (68-77 degrees | Nr | N |
| with short excursions allowed 59-86 degrees) | Yes | No |



| Compounding records including validation of each ingredient and amount by the | | |
|----------------------------------------------------------------------------------------|-----|----|
| pharmacist approving the product compounded | Yes | No |
| Documentation of extended beyond use dates | Yes | No |
| Training records for non-hazardous and hazardous compounding (if applicable) | Yes | No |
| Certification of each individual's proficiency and competency for the highest level | | |
| of compounding they will do | Yes | No |
| Cleaning/Calibration/Maintenance and sanitation records for non-sterile | | |
| environments | Yes | No |
| Certifications of equipment used and including testing of the equipment if | | |
| applicable: | | |
| Autoclaves, Ovens, Scales, Automatic Compounding devices | Yes | No |
| Refrigerator and Freezer records for any excursions out of required range | | |
| NAC639.525-527 | Yes | No |
| Records of tracking, recalling and destroying the drug products compounded by | | |
| the pharmacy | Yes | No |
| Certificates of Analysis | Yes | No |
| | | |
| | | |
| | | |
| | | |
| | | |
| Policies and Procedures (Write in the page reference for your policy and procedures if | | |
| the following apply to your facility or indicate NA: | | |
| | | |
| ABELING | 1 1 | |

LABELING 639.6703

STANDARDS FOR COMPOUNDING AND DISPENSING GENERALLY

639.67015 Establishment of policies and procedures

STANDARDS FOR COMPOUNDING AND DISPENSING NONSTERILE PRODUCTS 639.67035 Establishment of policies and procedures

It is affirmed that all information provided herein is true and correct to the best of my knowledge and belief and it is recognized that providing information known to be false may result in disciplinary action.



| REMARKS: | |
|----------|--|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |



| |
|------|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |



If you are required to provide any documentation to the inspector via fax or email attach a copy of the document(s) to this inspection form for future review. If you are required to fax or email information, fax to 270, 200 for inspection form for future review. If you are required to fax or email information, fax to

702-486-7903 for inspections completed by the Las Vegas Board office or 775-850-1444 for inspections completed by the Reno office. Clearly identify the facility on all documents.

If you are required to fill out a sterile, institutional or retail inspection form, refer to the remarks section of those forms for any additional remarks, suggestions, to do's or citations.

Print Name

Pharmacist Signature

Date

Board of Pharmacy Inspector

Date